CanvOI, an Oncology Intelligence Foundation Model: Scaling FLOPS Differently
This work addresses the problem of limited labeled data and complex clinical questions in digital oncopathology for cancer patients, representing an incremental advancement by optimizing computational resources.
The paper tackled the challenge of developing robust AI tools for digital oncopathology by introducing CanvOI, a foundation model that modifies input image characteristics, achieving state-of-the-art performance with a 1.5-7.4% improvement in averaged AUC on cancer-related benchmarks.
The rapidly evolving field of digital oncopathology faces significant challenges, including the need to address diverse and complex clinical questions, often involving rare conditions, with limited availability of labeled data. These limitations hinder the development of robust AI-driven tools in the biomedical space, where accuracy in probabilistic determinations is of utmost importance. To address this, digital pathology foundation models have begun to emerge, typically developed with the size and diversity of the pre-training dataset and model parameters in mind. Here, we present CanvOI, a ViT-g/10-based foundation model designed to enhance the capabilities of digital pathology by addressing these challenges through a different approach. Considering the unique nature of oncologic histopathological images and the requirements from the embeddings to provide meaningful representations for Multiple Instance Learning (MIL) downstream models, we chose to modify the input image characteristics. By introducing larger tile sizes (380 x 380 pixels) and smaller patch sizes (10 x 10 pixels), we were able to optimize the model's performance, pushing computational resources in a new direction and achieving state-of-the-art performance on cancer-related benchmarks. CanvOI demonstrated a 1.5-7.4% improvement in averaged AUC compared to other leading foundation models built for digital pathology. Moreover, our results demonstrate that CanvOI significantly outperformed the other models, with the performance gap widening substantially when trained on just 10% of the initial cohort. This work highlights an alternative approach that, if integrated with traditional development approaches, has the potential to advance Oncology Intelligence (OI), overcome some of the current barriers and ultimately improve the clinical outcome of cancer patients.